A team that includes a RIKEN researcher has refined a lab test for measuring protein aggregate levels in samples from patients with certain neurodegenerative diseases. This has the potential to ...

Prothena Co. plc (NASDAQ:PRTA – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eight ...

A fluorescent micrograph of a section of brain affected by Parkinson's disease. Neuron nuclei are blue, while the protein ...

This has the potential to improve diagnosis and drug development for these diseases. Synucleinopathies are neurodegenerative diseases such as Parkinson’s disease and dementia with Lewy bodies. They ...

Research analysts at Zacks Research boosted their Q1 2025 earnings estimates for Prothena in a research report issued on ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment ...

Across two cohorts, the Automated Imaging Differentiation for Parkinsonism (AIDP) machine learning model distinguished ...

Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as MSA and Parkinson's disease. It is a monoclonal antibody (mAb) that selectively targets soluble ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

Sleep disorders are a group of conditions in which the normal sleep pattern or sleep behaviours are disturbed. Primary sleep disorders include insomnia, hypersomnia, obstructive sleep apnoea and ...